Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe?

International Journal of Epidemiology

Volumn 28, Issue 3, 1999, Pages 541-549

  Prins, Maria ^a   Brettle, Raymond P ^b   Robertson, J Roy ^c   Hernández Aguado, Ildefonso ^d   Broers, Barbara ^e   Carré, Nicolas ^f   Goldberg, David J ^g   Zangerle, Robert ^h   Coutinho, Roel A ^a,i   Van Den Hoek, Anneke ^a  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b CITY HOSPITAL   (United Kingdom)

^c Edinburgh Drug Addiction Study   (United Kingdom)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f BICÊTRE HOSPITAL   (France)

^g RUCHILL HOSPITAL   (United Kingdom)

^h UNIVERSITY OF INNSBRUCK   (Austria)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Drug users; Europe; Geographical variation; HIV disease progression; Seroconverters

Indexed keywords

DISEASE PREVALENCE; HUMAN IMMUNODEFICIENCY VIRUS; MEDICAL GEOGRAPHY; REGIONAL PATTERN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; DEMOGRAPHY; DISEASE COURSE; EUROPE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; SEROCONVERSION; SOCIOECONOMICS;

ADULT; CD4 LYMPHOCYTE COUNT; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE PROGRESSION; EUROPE; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; SUBSTANCE ABUSE, INTRAVENOUS;

EUROPE;

EID: 0032997956     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/28.3.541     Document Type: Article

References (48)

1. European Centre for the Epidemiological Monitoring of AIDS. HIV/ AIDS Surveillance in Europe. Quarterly report, 1997, p.56.
2. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529-34.
3. Mariotto AB, Mariotti S, Pezzotti P, Rezza G, Verdecchia A. Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. Am J Epidemiol 1992;135:428-37.
4. Galai N, Vlahov D, Margolick JB, Chen K, Graham NMH, Muñoz A. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:66-74.
5. Prins M, Veugelers PJ for the European Seroconverter Study and the Tricontinental Seroconverter Study. Comparison of progression and nonprogression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. AIDS 1997;11:621-31.
6. Spijkerman IJB, Langendam MW, Veugelers PJ et al. Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology 1996;7:571-77.
7. Pezzoki P, Phillips AN, Dorrucci M et al. HIV Italian Seroconversion Study Group. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. Br Med J 1996;313:583-86.
8. Carré N, Prins M, Meyer L et al. Has the rate of progression to AIDS changed in recent years? AIDS 1997;11:1611-18.
9. Lundgren JD, Pedersen C, Clumeck N et al. Survival differences in European patients with AIDS, 1979-89. Br Med J 1994;308:1068-73.
10. Prins M, Hernández Aguado I, Brettle RP et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997;11:1747-56.
11. Hernández-Aguado I, Bolumar F. Determinants of HIV-1 infection in intravenous drug users in Valencia, Spain, 1987-1991. Int J Epidemiol 1993;22:537-42.
12. Skidmore CA, Robertson JR, Robertson AA, Elton RA. After the epidemic: follow up study of HIV seroprevalence and changing patterns of drug use. Br Med J 1990;300:219-23.
13. Brettle RP, Bisset K, Burns S et al. Human immunodeficiency virus and drug misuse: the Edinburgh experience. Br Med J 1987;295:421-24.
14. van den Hoek JAR, Coutinho RA, van Haastrecht HJA, van Zadelhoff AW, Goudsmit J. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988;2:55-60.
15. Ledergerber B, Von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994;39:387-94.
16. Carré N, Deveau C, Belanger F et al. SEROCO Study Group. Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. AIDS 1994;8:797-802.
17. Goldberg DJ, Emslie JA, Smyth W, Reid D. A system for surveillance of voluntary HIV testing: results of the first 2 years 1989-1990. AIDS 1992;6:495-500.
18. Zangerle R, Fuchs D, Rossler H et al. Trends in HIV infection among intravenous drug users in Innsbruck, Austria. J Acquir Immune Defic Syndr 1992;5:865-71.
19. Geskus RB, van Griensven GJP, Albrecht-van Lent N, Coutinho RA. The probability to be AIDS free beyond 10 years after seroconversion. XI International Conference an AIDS, Vancouver 1996 (abstract Tu.C.434).
20. SAS Institute Inc. SAS/STAT Software: Changes enhancements through release 6.11. Cary, NC: SAS Institute Inc., 1996.
21. Lang W, Perkins H, Anderson R et al. Patterns of T-lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr 1989;2:63-69.
22. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987; 36:1S-15S.
23. Hessol NA, Koblin BA, van Griensven GJP et al. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol 1994;139:1077-87.
24. Veugelers PJ, Schlechter MT, Tindall B et al. Differences in time from HIV seroconversion to CD4+ lymphocyte end-points and AIDS in cohorts of homosexual men. AIDS 1993;7:1325-29.
25. Biggar RJ, International Registry of Seroconverters. AIDS incubation in 1891 HIV seroconverters from different exposure groups. AIDS 1990;4:1059-66.
26. Muñoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997;11:S69-S76.
27. Hoover DR, Peng Y, Saah AJ, Detels RR, Rinaldo CR, Phair JP. Projecting disease when death is likely. Am J Epidemiol 1996;143: 943-52.
28. Rosenberg PS, Goedert JJ, Biggar RJ for the Multicenter Hemophilia Cohort Study and the International Registry of Seroconverters. Effect of age at seroconversion on the natural AIDS incubation distribution. AIDS 1994;8:803-10.
29. Ronald PJM, Robertson JR, Elton RA. Continued drug use and other cofactors for progression to AIDS among injecting drug users. AIDS 1994;8:339-43.
30. Operskalski EA, Stram DO, Lee H et al. Transfusion Safety Study Group. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. J Infect Dis 1995;172:648-55.
31. Brettle RP, McNeil AJ, Burns S et al. Progression of HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-1985. AIDS 1996;10:419-30.
32. Muñoz A, Xu J. Models for the incubation period of AIDS and variations according to age and period. Stat Med 1996;15:2459-73.
33. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996;347:1573-79.
34. Veugelers PJ, Page KA, Tindall B et al. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol 1994;140:747-58.
35. Cozzi Lepri A, Pezzotti P, Dorrucci M, Phillips AN, Rezza G. The Italian Seroconversion Study. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Br Med J 1994;309:1537-42.
36. Phillips AN, Antunes F, Stergious G et al. A sex comparison of rates of new AIDS defining disease and death in 2554 AIDS cases. AIDS 1994;8:831-35.
37. Donahoe RM, Byrd LD, McClure HM et al. Consequences of opiate-dependency in a monkey model of AIDS. In: Friedman H et al. (eds). Drugs of Abuse, Immunity, and Immunodeficiency. New York: Plenum Press, 1993, pp.21-28.
38. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH. Morphine promotes the growth of HIV-1 in human peripheral blood monocuclear cell cocultures. AIDS 1990;4:869-73.
39. Pillai R, Nair BS, Watson RR. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network (Review). Arch Toxicol 1991;65:609-17.
40. Donahoe RM, Falek A, Madden JJ et al. Effects of cocaine and other drugs of abuse on immune function. In: Friedman H et al. (eds). Drugs of Abuse, Immunity, and Immunodeficiency. New York: Plenum Press 1991, pp.143-50.
41. Weber R, Ledergerber B, Opravil M, Siegenthaler W, Lüthy R. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. Br Med J 1990;301:1362-65.
42. The Italian Seroconversion Study. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. AIDS 1992;6:421-26.
43. Mientjes GHC, van Ameijden EJC, van den Hoek JAR, Goudsmit J, Miedema F, Coutinho RA. Progression of HIV infection among injecting drug users: indications for a lower rate of progression among those who have frequently borrowed injecting equipment. AIDS 1993;7:1363-70.
44. Selwyn PA, Alcabes P, Hartel D et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992;327:1697-703.
45. Muñoz A, Vlahov D, Solomon L et al. Prognostic indicators for development of AIDS among intravenous drug users. J Acquir Immune Defic Syndr 1992;5:694-700.
46. Brown LS, Jr., Siddiqui NS, Chu AF. Natural history of HIV-1 infection and predictors of survival in a cohort of HIV-1 seropositive injecting drug users. J Natl Med Assoc 1996;88:37-42.
47. Lyles CM, Margolick JB, Astemborski J et al. The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users. AIDS 1997;11:1255-62.
48. Krol A, Flynn C, Vlahov D, Miedema F, Coutinho RA, van Ameijden EJC. New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users. Drug Alc Depend (in press).